

**CLAIMS:**

1. (Currently amended) A composition comprising a multispecific ligand comprising a at least a first ligand binding moiety which specifically binds to a first ligand having a first biodistribution and a second ligand binding moiety which specifically binds to a second ligand having a second biodistribution different from that of the first ligand, and wherein the affinity of the first and second ligand binding moieties are different and selected to bias the biodistribution of the multispecific ligand.
2. (Original) The composition according to claim 1, further comprising a physiologically acceptable excipient.
3. (Currently amended) The composition according to claim 2, wherein the multispecific ligand is ~~comprises~~ a bispecific antibody.
4. (Original) The composition according to claim 3, wherein the affinity of said first ligand binding moiety for the first ligand is higher than the affinity of the second ligand binding moiety for the second ligand and wherein the biodistribution of the multispecific ligand favours the first ligand.
5. (Original) The composition according to claim 4, wherein the first and second ligands have overlapping biodistributions.
6. (Original) The composition according to claim 5, wherein the first ligand is present on a first target cell population and wherein said second ligand is present on a second target cell population comprising the first target cell population and wherein the biodistribution of the multispecific ligand favours the first target cell population.

7. (Currently amended) The composition according to claim 1, wherein said first ligand is a cell surface marker associated with one or more specific cell populations, ~~infectious or parasitic agents~~, diseased cells, or disease-associated cells.
8. (Original) The composition according to claim 7, wherein said marker is an antigen.
9. (Original) The composition according to claim 7, wherein said marker is an epitope.
10. (Withdrawn) The composition according to claim 7, wherein said marker is a CD marker.
11. (Withdrawn) The composition according to claim 10, wherein said marker is CD4.
12. (Original) The composition according to claim 7, wherein said marker is specifically associated with a cancer cell or pre-cancerous cell.
13. (Currently amended) The composition according to claim 7 ~~44~~, wherein said second ligand is a CXCR4 receptor.
14. (Withdrawn) The composition according to claim 7, wherein said marker is associated with an immune cell that is susceptible to viral infection.
15. (Withdrawn) The composition according to claim 7, wherein said marker is specifically associated with an autoimmune disorder of rheumatic disease.

16. (Withdrawn) The composition according to claim 7, wherein said marker is associated with a specific tissue type.

17. (Withdrawn) The composition according to claim 7, wherein said marker is associated with a specific organ.

18. (Withdrawn) The composition according to claim 7, wherein said marker is associated with a cell of tissue of specific origin or class.

19. (Withdrawn) The composition according to claim 7, wherein said marker is an MHC-peptide complex.

20. (Withdrawn) The composition according to claim 7, wherein said marker is a cell surface immunoglobulin.

21-130. (Canceled)